China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions’ subsidiary Porton Advanced, a specialist in advanced therapy medicinal products (ATMPs), has formed a partnership with US-based biotech firm Eureka Therapeutics, Inc. The collaboration focuses on the global clinical development of T-cell therapies, with financial details remaining undisclosed.
Eureka Therapeutics’ Technology Platforms
Eureka Therapeutics brings to the table its proprietary ARTEMIS cell receptor and E-ALPHA antibody discovery platforms. These innovative platforms enable the development of novel T-cell therapies targeting both solid tumors and hematologic malignancies, positioning the company at the forefront of cancer immunotherapy research.
Strategic Collaboration Benefits
The partnership combines Porton Advanced’s expertise in ATMPs with Eureka Therapeutics’ cutting-edge technology, creating a powerful synergy for advancing T-cell therapy solutions globally. This collaboration holds significant promise for expanding treatment options and improving outcomes for cancer patients worldwide.-Fineline Info & Tech
Leave a Reply